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Introduction
Mutations in the gene encoding NLRP3 cause a spectrum
of autoinflammatory diseases known as the cryopyrin-
associated periodic syndromes (CAPS). NLRP3 is a key
component of one of several distinct cytoplasmic multi-
protein complexes (inflammasomes) that mediate the
maturation of the proinflammatory cytokine interleukin-
1b (IL-1b) by activating caspase-1. Although several
models for inflammasome activation, such as K+ efflux,
generation of reactive oxygen species, and lysosomal
destabilization have been proposed, the precise molecular
mechanism of NLRP3 inflammasome activation, as well
as the mechanism by which CAPS-associated mutations
activate NLRP3, remains to be elucidated.
Objectives
To investigate how extracellular DAMP signals activate
the NLRP3 inflammasome and the molecular pathogenesis
of CAPS.
Methods
Using a combination of genetic, pharmacological, and bio-
chemical approaches, we provide evidence that the CaSR
is essential for NLRP3 inflammasome activation, which is
directly controlled by intracellular Ca2+ and cAMP.
Results
Ca2+ or other CaSR agonists activate the NLRP3 inflam-
masome in the absence of exogenous ATP, whereas
knockdown of CaSR reduces inflammasome activation
in response to known NLRP3 activators. The CaSR acti-
vates the NLRP3 inflammasome through phospholipase
C (PLC), which catalyzes inositol trisphosphate (IP3)
production and thereby induces release of Ca2+ from
endoplasmic reticulum (ER) stores. The increased cyto-
plasmic Ca2+ promotes the assembly of inflammasome
components, and intracellular Ca2+ is required for spon-
taneous inflammasome activity in cells from CAPS
patients. CaSR stimulation also results in reduced intra-
cellular cAMP, which independently activates the NLRP3
inflammasome. cAMP binds to NLRP3 directly to inhibit
inflammasome assembly, and downregulation of cAMP
relieves this inhibition. The binding affinity of cAMP for
CAPS-associated mutant NLRP3 is substantially lower
than for wild-type NLRP3, and the uncontrolled mature
IL-1b production from CAPS patients’ peripheral blood
mononuclear cells is attenuated by increasing cAMP.
Conclusion
Taken together, these findings suggest that Ca2+ and
cAMP are two key molecular regulators of the NLRP3
inflammasome that have critical roles in the molecular
pathogenesis of CAPS. In addition, our data suggest a
broader spectrum of potential targets for therapy of CAPS
as well as other inflammatory conditions involving the
NLRP3 inflammasome, including gout, type 2 diabetes
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